DISCLOSURE OF UNAPPROVED STATUS OF PRODUCTS DOES NOT PREVENT EXCHANGE OF INFO ON OFF-LABEL USES, FDA MAINTAINS IN REQUEST FOR COMMENTS ON CME POLICY